Drugs / aSMDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04976153 | May 2022 → Dec 2027 expected | — | Innovacell GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aSMDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04976153 ↗ |
| Modality | Cell therapy | “Autologous Muscle Derived Cells for injection into the external anal sphincter” NCT04976153 ↗ |